PharmaJet Partner, Scancell, Announces Phase 2 Melanoma DNA Vaccine Trial will include Needle-free Delivery

Published studies show improved immunogenicity of PharmaJet System for DNA vaccines

GOLDEN, Colo. — August 2, 2022 — PharmaJet® , a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that its partner, Scancell, will include needle-free delivery of their Phase 2 clinical study for treatment of patients with advanced melanoma.

Skin cancer is by far the most common of all cancers. Melanoma accounts for only about 1% of skin cancers but causes a large majority of skin cancer deaths. The American Cancer Society’s estimates about 100,000 new melanomas will be diagnosed in the United States in 2022 and nearly 8% of those diagnosed are expected to die from it.1

Scancell’s immunotherapy platform uses the body’s immune system to identify, attack and destroy tumors. In the Phase 1/2 clinical trial, 89% of the resected patients survived for more than 5 years following vaccination with their SCIB1 vaccine. The Phase 2 study is designed to assess whether the addition of SCIB1 treatment to pembrolizumab or ipilimumab/nivolumab results in an improvement in patient outcomes for patients with metastatic disease. The updated protocol adds needle-free injection with the PharmaJet Stratis® System as Scancell believes needle-free delivery could improve patient acceptance. Scancell is also using one of PharmaJet’s WHO-prequalified Needle-free Injection Systems for delivery of two SARS-CoV-2 DNA vaccine candidates, currently being evaluated in South Africa.

Chris Cappello, President and CEO, PharmaJet commented, “We are pleased to be partnering with Scancell as they start their Phase 2 trial with a needle-free delivery option for patients with advanced melanoma. In addition to increasing patient acceptance, our partners have published data showing superior results to electroporation, and improved immunogenicity with DNA vaccines.”

For more information about PharmaJet visit

Refer to Instructions for Use to ensure safe injections and to review risks.


About PharmaJet
PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet’s Needle-free Injection Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit Follow us on LinkedIn.

About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company’s unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).

For further information about Scancell, please visit: